Abstract: Objectives: To compare the administration of gemcitabine (GEM) alone with GEM-cisplatin (DDP) combination chemotherapy in patients with advanced stage pancreatic cancer (APCa). Methods: MEDLINE, EMBASE and ASCO searches were supplemented with information from data retrievals and registers. A quantitative meta-analysis was carried out using updated information and the inclusion criterion from all available randomized controlled trials. The primary meta-analysis was conducted based on the overall survival rate (OS). The second analysis used objective remission rate (ORR) and toxicity. Results: The meta-analysis included 6 randomized controlled trials. There was no significant improvement in the GEM-DDP combination group for the 6-month survival rate (P=0.24) and the clinical benefit rate (P=0.58). There was a significant improvement in the GEM-DDP combination group in terms of ORR (RD=6%, P=0.05). Moreover, there was a significant improvement in the combination group for 6-month TTP/TTF (RD=9%, P=0.02). However, WHO grade 3-4 toxicity was more frequent for the GEM-DDP combination group along with neutropenia (RD=6%, P=0.08), thrombocytopenia (RD=8%, P=0.17) and vomiting/nausea (RD=11%, P=0.07), but none of these parameters showed a significant difference when compared to the group treated with GEM alone. Conclusion: The regimen of GEM plus DDP had no significant survival benefit compared to GEM alone. GEM-DDP combination should not be recommended as a therapeutic protocol for APCa. Administration of GEMalone is still an optimal treatment for patients with APCa.